Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) EBIT Margin (2016 - 2025)

Vistagen Therapeutics' EBIT Margin history spans 11 years, with the latest figure at 6452.48% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 906.0% year-over-year to 6452.48%; the TTM value through Dec 2025 reached 8848.61%, down 128209.0%, while the annual FY2025 figure was 11517.08%, 841360.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 6452.48% at Vistagen Therapeutics, up from 7772.87% in the prior quarter.
  • Across five years, EBIT Margin topped out at 96633.33% in Q1 2025 and bottomed at 14441.67% in Q2 2024.
  • The 4-year median for EBIT Margin is 3575.42% (2021), against an average of 1572.98%.
  • The largest annual shift saw EBIT Margin plummeted -1094267bps in 2024 before it soared 10239056bps in 2025.
  • A 4-year view of EBIT Margin shows it stood at 2943.85% in 2021, then surged by 35bps to 1918.25% in 2023, then plummeted by -237bps to 6461.54% in 2024, then grew by 0bps to 6452.48% in 2025.
  • Per Business Quant, the three most recent readings for VTGN's EBIT Margin are 6452.48% (Q4 2025), 7772.87% (Q3 2025), and 6477.05% (Q2 2025).